Pfizer reports third-quarter 2010 results

Third-Quarter 2010 Revenues of $16.2 Billion. Third-Quarter 2010 Adjusted Diluted EPS(1) of $0.54; Reported Diluted EPS (2) of $0.11. Tightens Ranges for 2010 Financial Guidance Components, Increases Range for Adjusted Diluted EPS(1) and Reduces Range for Reported Diluted EPS(2); Reaffirms 2012 Financial Targets. Advances Strategic Priorities with Agreement to Acquire King Pharmaceuticals, Inc., Acquisition of FoldRx, Alliance with Biocon and Pending Alliance with Laboratorio Teuto Brasileiro...

Continuar leyendo en el sitio de Pfizer >>